SM
BLPH

Sabby Management’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Sabby Management’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-20,594
Closed -$202K – 118
2019
Q1 		$202K Buy
+20,594
New +$227K 0.1% 50
2017
Q1 		– Sell
-52,657
Closed -$414K – 349
2016
Q4 		$414K Buy
+52,657
New +$733K 0.02% 210
2015
Q3 		– Sell
-2,382
Closed -$283K – 420
2015
Q2 		$283K Buy
2,382
+382
+19% +$51.9K 0.01% 284
2015
Q1 		$275K Buy
+2,000
New +$311K 0.01% 258

Other funds holding BLPH

NMVA
New Mountain Vantage Advisers New York $4.33B AUM 35.3% 1-Year Est. Return
PCM
Puissance Capital Management New York $17.3M AUM 149.36% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Sabby Management's BLPH Position: Q2 2019 in Review

Sabby Management sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q2 2019, closing a stake of 20,594 shares — an estimated $202K sold.

Sabby Management first reported a position in BLPH in Q1 2015 and held it in 4 quarters. The position peaked at $414K in Q4 2016. 26 funds tracked by Wall St. Rank hold BLPH as of Q2 2019.

  • Sabby Management reported no remaining Bellerophon Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
  • Sabby Management sold 20,594 Bellerophon Therapeutics, Inc. shares in Q2 2019, an estimated $202K.
  • Sabby Management first reported a position in Bellerophon Therapeutics, Inc. in Q1 2015 and held it in 4 quarters.
  • Sabby Management's Bellerophon Therapeutics, Inc. position peaked at $414K in Q4 2016.
  • 26 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q2 2019.

Based on Sabby Management's 13F filing for Q2 2019, filed 14 Aug 2019.